ImmunityBio, Inc. IBRX
Set alert
8.29 USD -0.45 -5.15%
At close
8.34 +0.05 +0.60%
Pre-market · Nov 2, 4:53 AM ET
8.12 Day range 8.72
1.95 52-week range 12.43
- YTD
- +318.69%
- 1 year
- +245.42%
- Open
- 8.48
- Prev close
- 8.74
- Mkt cap
- 8.79B
- Vol
- 8.91M
- Avg vol
- 11.48M
- EPS
- -0.96
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.12
- High
- 8.72
- Forward P/E
- -113.05
- Beta
- 0.03
- Short ratio
- 7.96
- Inst. own
- 19.80%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 8.70
- 200-d avg
- 7.88
- 1y target
- 14.25
5Y chart
Events in this range
- Aug 5, 2025Earnings: -0.1; estimate -0.1; surprise 0%
- Nov 4, 2025Earnings: -0.07; estimate -0.1; surprise 30%
- Feb 23, 2026Earnings: -0.06; estimate -0.08; surprise 25%
- May 5, 2026Rating: D. Boral Capital · Buy → Buy
- May 7, 2026Earnings: -0.62; estimate -0.08; surprise -675%
- May 20, 2026Rating: HC Wainwright & Co. · Buy → Buy
- May 21, 2026Rating: BTIG · Buy → Buy
- Jun 2, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Aug 4, 2026Earnings: -0.22; estimate -0.08; surprise -175%
- Oct 15, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Oct 15, 2026Rating: Jefferies · Buy → Buy
- Nov 3, 2026Earnings: —; estimate -0.07; surprise —%
Signals (98)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 26, 2026 | 1 week ago |
| SMA: Bearish | Oct 19, 2026 | 2 weeks ago |
| RSI: Overbought | Oct 5, 2026 | 4 weeks ago |
| MACD: Buy Signal | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| SMA: Bearish | Jul 13, 2026 | 3 months ago |
| SMA: Bullish | Jun 22, 2026 | 4 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 20, 2026 | 6 months ago |
| SMA: Bearish | Mar 23, 2026 | 7 months ago |
| SMA: Bullish | Jan 12, 2026 | 9 months ago |
| RSI: Overbought | Jan 12, 2026 | 9 months ago |
| SMA: Bullish | Jan 5, 2026 | 10 months ago |
| MACD: Buy Signal | Jan 5, 2026 | 10 months ago |
| MACD: Sell Signal | Dec 29, 2025 | 10 months ago |
| SMA: Bearish | Dec 15, 2025 | 10 months ago |
| SMA: Bullish | Dec 8, 2025 | 10 months ago |
| SMA: Bearish | Dec 1, 2025 | 11 months ago |
| MACD: Buy Signal | Dec 1, 2025 | 11 months ago |
| SMA: Bullish | Nov 24, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 10, 2025 | 11 months ago |
| SMA: Bearish | Oct 6, 2025 | 1 year ago |
| SMA: Bearish | Sep 22, 2025 | 1 year ago |
| SMA: Bullish | Sep 15, 2025 | 1 year ago |
| SMA: Bullish | Sep 8, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 1, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 25, 2025 | 1 year ago |
| SMA: Bearish | Jul 28, 2025 | 1 year ago |
| SMA: Bullish | Jul 21, 2025 | 1 year ago |
| SMA: Bearish | Jul 14, 2025 | 1 year ago |
| SMA: Bullish | May 26, 2025 | 1 year ago |
| SMA: Bearish | May 19, 2025 | 1 year ago |
| SMA: Bullish | May 12, 2025 | 1 year ago |
| MACD: Buy Signal | May 12, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 14, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 24, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 17, 2025 | 1 year ago |
| SMA: Bearish | Mar 3, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 10, 2025 | 1 year ago |
| SMA: Bullish | Jan 27, 2025 | 1 year ago |
| SMA: Bearish | Dec 9, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 9, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| SMA: Bullish | Nov 4, 2024 | 1 year ago |
| MACD: Buy Signal | Oct 28, 2024 | 2 years ago |
| SMA: Bullish | Oct 21, 2024 | 2 years ago |
| SMA: Bearish | Jul 22, 2024 | 2 years ago |
| SMA: Bearish | Jun 24, 2024 | 2 years ago |
| SMA: Bullish | Jun 17, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 3, 2024 | 2 years ago |
| SMA: Bearish | May 20, 2024 | 2 years ago |
| RSI: Overbought | Apr 29, 2024 | 2 years ago |
| SMA: Bullish | Feb 26, 2024 | 2 years ago |
| MACD: Buy Signal | Feb 26, 2024 | 2 years ago |
| SMA: Bearish | Feb 19, 2024 | 2 years ago |
| MACD: Sell Signal | Feb 19, 2024 | 2 years ago |
| SMA: Bullish | Jan 29, 2024 | 2 years ago |
| SMA: Bearish | Jan 8, 2024 | 2 years ago |
| SMA: Bullish | Oct 23, 2023 | 3 years ago |
| SMA: Bullish | Oct 23, 2023 | 3 years ago |
| MACD: Buy Signal | Oct 23, 2023 | 3 years ago |
| MACD: Sell Signal | Aug 7, 2023 | 3 years ago |
| SMA: Bearish | Jul 24, 2023 | 3 years ago |
| SMA: Bullish | Jul 10, 2023 | 3 years ago |
| SMA: Bearish | Jun 12, 2023 | 3 years ago |
| SMA: Bullish | May 29, 2023 | 3 years ago |
| SMA: Bearish | May 22, 2023 | 3 years ago |
| SMA: Bullish | May 15, 2023 | 3 years ago |
| SMA: Bearish | May 8, 2023 | 3 years ago |
| SMA: Bearish | May 8, 2023 | 3 years ago |
| SMA: Bullish | May 1, 2023 | 3 years ago |
| MACD: Buy Signal | May 1, 2023 | 3 years ago |
| SMA: Bullish | Apr 17, 2023 | 3 years ago |
| RSI: Oversold | Mar 6, 2023 | 3 years ago |
| SMA: Bearish | Jan 2, 2023 | 3 years ago |
| MACD: Sell Signal | Jan 2, 2023 | 3 years ago |
| SMA: Bearish | Dec 19, 2022 | 3 years ago |
| SMA: Bullish | Nov 21, 2022 | 3 years ago |
| SMA: Bearish | Nov 14, 2022 | 3 years ago |
| SMA: Bullish | Nov 7, 2022 | 3 years ago |
| SMA: Bearish | Oct 31, 2022 | 4 years ago |
| SMA: Bullish | Sep 5, 2022 | 4 years ago |
| SMA: Bearish | Aug 15, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| SMA: Bearish | Jul 25, 2022 | 4 years ago |
| MACD: Buy Signal | Jul 4, 2022 | 4 years ago |
| SMA: Bullish | Jun 20, 2022 | 4 years ago |
| RSI: Oversold | Jun 6, 2022 | 4 years ago |
| RSI: Oversold | Apr 18, 2022 | 4 years ago |
| SMA: Bearish | Feb 28, 2022 | 4 years ago |
| SMA: Bullish | Feb 14, 2022 | 4 years ago |
| SMA: Bearish | Jan 17, 2022 | 4 years ago |
| SMA: Bullish | Jan 10, 2022 | 4 years ago |
Key statistics
- Market cap
- 8.79B
- Enterprise value
- 10.13B
- Trailing P/E
- 0.00
- Forward P/E
- -113.05
- PEG ratio
- 0.00
- Price / sales
- 52.99
- Price / book
- 0.00
- EPS (TTM)
- -0.96
- Beta
- 0.03
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 165.79M
- Revenue growth
- 93.90%
- Free cash flow
- -186.56M
- Total cash
- 357.37M
- Total debt
- 1.23B
- Return on equity
- 0.00%
- Shares outstanding
- 1.06B
- Short % of float
- 30.67%
- 50-day average
- 8.70
- 200-day average
- 7.88
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 14.25 +71.9% upside
Now 8.29
- Target (low)
- 12.00
- Target (mean)
- 14.25
- Target (high)
- 16.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate -0.05.
Financials — quick view
IBRX Revenue — quarterly 51.24M
IBRX Net income — quarterly -230.38M
IBRX EPS — quarterly -0.22
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | -0.07 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | -0.08 | -0.22 | -0.14 | -175.00% |
| May 7, 2026 | Mar 31, 2026 | -0.08 | -0.62 | -0.54 | -675.00% |
| Feb 23, 2026 | Dec 31, 2025 | -0.08 | -0.06 | +0.02 | +25.00% |
| Nov 4, 2025 | Sep 30, 2025 | -0.10 | -0.07 | +0.03 | +30.00% |
| Aug 5, 2025 | Jun 30, 2025 | -0.10 | -0.10 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 15, 2026 | Jefferies | main | Buy | Buy |
| Oct 15, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 2, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| May 21, 2026 | BTIG | reit | Buy | Buy |
| May 20, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| May 5, 2026 | D. Boral Capital | main | Buy | Buy |
About ImmunityBio, Inc.
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- immunitybio.com
News
- Jim Cramer Calls Celsius 'A Second-Rate Monster,' Says Stick With the Original
- ImmunityBio, Inc. $IBRX Stake Trimmed by Davidson Kahn Capital Management LLC
- ImmunityBio Anticipates Reporting Topline Results In November 2026, Remains On Track To Submit sBLA To FDA In Q4 2026 For ANKTIVA Plus BCG In Patients With BCG-Naïve NMIBC
- ImmunityBio Completes Database Lock For Cohort A Of QUILT-2.005, Randomized, Controlled, Registrational Trial Evaluating ANKTIVA In Combination With BCG Versus BCG Alone In Patients With BCG-Naïve NMIBC
- 9 Health Care Stocks Whale Activity In Today’s Session
- ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment
- ImmunityBio Announces Data From Its Phase 2/3 QUILT-3.032 Trial Of ANKTIVA In Combination With Bacillus Calmette-Guerin Demonstrates 71% Complete Response Rate In Participants With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ
- Jefferies Maintains Buy on ImmunityBio, Raises Price Target to $14
- ImmunityBio Stock Climbs Thursday: What's Going On?
- HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target
Your note
Sign in to keep a note on IBRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADCOCK RICHARD | Chief Executive Officer | Conversion of Exercise of derivative security | Feb 19, 2026 | 560,344 |
| COHEN CHERYL L | Director | Sale | Oct 1, 2026 | 100,309 |
| REGAN LAUER | Officer | Conversion of Exercise of derivative security | Feb 19, 2026 | 115,875 |
| SACHS DAVID C | Chief Financial Officer | Conversion of Exercise of derivative security | Feb 19, 2026 | 300,143 |
| SELECKY CHRISTOBEL E. | Director | Sale | Jun 30, 2026 | 0 |
| SIMON BARRY J. M.D. | Director | Sale | Oct 4, 2026 | 2,777,790 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 3.22% | 34,083,262 | 282.55M | Jun 29, 2026 |
| State Street Corporation | 2.02% | 21,398,438 | 177.39M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 1.69% | 17,863,911 | 148.09M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 1.48% | 15,691,579 | 130.08M | Jun 29, 2026 |
| Shaw D.E. & Co., Inc. | 1.09% | 11,551,019 | 95.76M | Jun 29, 2026 |
| Two Sigma Investments, LP | 1.05% | 11,097,106 | 92.00M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.10% | 11,702,382 | 97.01M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.09% | 11,597,491 | 96.14M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 0.94% | 9,991,183 | 82.83M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 0.79% | 8,399,273 | 69.63M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 0.46% | 4,852,894 | 40.23M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.40% | 4,224,658 | 35.02M | Jul 30, 2026 |